The Medicaid P & T Committee is comprised of up to 15 actively practicing healthcare professionals appointed by the Secretary of DHHR and acts in an advisory capacity to assist BMS in selecting drugs for the Preferred Drug List. Members may serve a maximum of three, three-year terms. Members are required to disclose their conflicts of interest, if any, and to maintain confidentiality of drug rebate information. The Committee meets three times per year and as necessary to review the PDL and new drugs as they become available.
The West Virginia Medicaid Pharmaceutical and Therapeutics Committee is committed to:
- Objectively recommending drugs for inclusion on the WV Preferred Drug List (PDL) that are effective and cost efficient, while providing maximum safety;
- Examine the scientific literature (found in labeling, drug compendia, and peer reviewed clinical literature) for sound clinical evidence that supports selecting specific drugs to be included on the PDL
- Ensure that the PDL provides for medically appropriate drug therapies for use in the general Medicaid population, allowing healthcare providers to care for the majority of their patients without a prior authorization request.
P&T Committee Members
Philip Galapon, MD, Chair
Scott Brown, PharmD, Vice Chair
John J. Bernabei, RPh
Krista Capehart, PharmD
Michael Cheshire, DO
Laura Davisson, MD
Toni DiChiacchio, DNP
David Gloss, MD
Brian Hardman, FNP-C
Mitzi Payne, MD
Charlie Rohrbaugh, RPh
Shelley Schliesser, PharmD
Chris Terpening, PharmD
P & T Committee Meetings
Speaker Sign-Up Process
Archived P&T Committee Meetings 2014-2017
Archived P&T Committee Meetings 2002-2013